



PATENT APPLICATION
Serial No. 09/509,391
Atty. Docket No. 702-000648

12
A
4/30/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit 1653

In re application of

Jeroen KRIJGSVELD et al. : ISOLATED AND RECOMBINANT
Serial No. 09/509,391 : ANTIMICROBIAL PEPTIDES
Filed July 7, 2000 : THROMBOCIDIN-1 (TC-1) AND
THROMBOCIDIN-2 (TC-2) OR
VARIANTS THEREOF

Examiner Sheridan K. Snedden

ISOLATED AND RECOMBINANT
ANTIMICROBIAL PEPTIDES
THROMBOCIDIN-1 (TC-1) AND
THROMBOCIDIN-2 (TC-2) OR
VARIANTS THEREOF

Pittsburgh, Pennsylvania
April 5, 2002

**Box SEQUENCE
Commissioner for Patents
Washington, DC 20231**

SEQUENCE AMENDMENT

RECEIVED

APR 17 2002

APR 2
TECH CENTER 1600/2900

Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed March 5, 2002, pursuant to 37 C.F.R. § 1.821 *et seq.*, Applicants submit the following Sequence Listing and corresponding computer readable form (CRF) for insertion into the specification. Applicants also submit the following amendment and remarks.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on April 5, 2002.

Ellen Harteau

Ellen H.  4/5/2002

Signature Date



Attorney's Docket No. 702-000648

RECEIVED

AMENDMENT TRANSMITTAL LETTER

APR 17 2002

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Serial No.: 09/509,391 Filing Date: July 7, 2000
Examiner: Sheridan K. Snedden Group Art Unit: 1653
Invention: "Isolated and Recombinant Antimicrobial Peptides Thrombocidin-1 (TC-1) and Thrombocidin-2 (TC-2) or Variants Thereof"

Transmitted herewith is an Amendment in the above-identified application.

- Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.
 A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
 No additional fee is required.
 The fee has been calculated as shown below:


No. of Claims	Highest No.	Small	Non-Small
After	Previously	Entity	Entity
<u>Amendment</u>	<u>Paid For</u>	<u>Present</u>	<u>Rate</u>
Total <u>14</u>	<u>20</u>	<u>-0-</u> X	\$ 9.00
Indep. <u>2</u>	<u>3</u>	<u>-0-</u> X	\$ 42.00
First Presentation of Multiple Dep. Claim		+ \$140.00	+ \$280.00
Total Additional Fee			\$ -0-

- A check in the amount of \$ _____ is enclosed to cover the filing fee.
 A check in the amount of \$ _____ is enclosed for a ____ month Petition for Extension of Time.
 The Commissioner is hereby authorized to charge payment of the following fees associated with this communication to Deposit Account No. 23-0650. Please refund any overpayment to Deposit Account No. 23-0650. An original and two copies of this sheet are enclosed.
 Any additional filing fees required under 37 CFR 1.16.
 Any patent application processing fees under 37 CFR 1.17.

April 5, 2002

Date

By



Barbara E. Johnson
Registration No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: (412) 471-8815
Facsimile: (412) 471-4094
E-mail: webblaw@webblaw.com

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on April 5, 2002.

Ellen Harteau



4/5/2002

Signature

Date